VEGFA and chronic kidney disease: Although the anti-VEGF dose and the incidence of systemic adverse events in ophthalmology are much lower than those in oncology [37], and previous articles reported no significant association between IVI with anti-VEGF and all-cause admission and cardiovascular adverse events irrespective of diabetic status [38,39], the target study population in our study comprised vascular vulnerable patients (i.e., diabetic patients, 45% with chronic kidney disease) and may have a higher complication rate even under a low dose of anti-VEGF therapy.